<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650285</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 246</org_study_id>
    <nct_id>NCT01650285</nct_id>
  </id_info>
  <brief_title>Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (&gt;0.1- &lt; 2.0 ng/mL)</brief_title>
  <official_title>Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (&gt;0.1- &lt; 2.0 ng/mL) Following Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a high relapse rate for patients who have undergone prostatectomy and have
      pathologic extracapsular prostate extension, positive surgical margins or seminal vesicle
      involvement (pathologic stage 3 disease). While adjuvant radiation improves progression-free
      and overall survival, approximately half of these patients will develop recurrence.
      Similarly, radiation therapy has become the standard salvage therapy for patients with rising
      PSA &gt;0.1 - &lt; 2.0 ng/mL. In common solid tumors such as NSCLC, head and neck cancer and upper
      gastrointestinal cancers, the addition of chemotherapy to radiation improves survival. It is
      hypothesized that the addition of radiosensitizing chemotherapy to standard adjuvant
      radiation will improve survival in patients with stage 3 prostate cancer after prostatectomy
      and patients with rising PSA &lt; 2.0 ng.mL without detectable disease. Taxanes are powerful
      radiation enhancers since they synchronize tumor cells in G2/M the most radiosensitive phase
      of the cell cycle.17,18 Cabazitaxel is the most active taxane in the treatment of prostate
      cancer. Therefore, we propose a phase I study establishing the optimal dose of cabazitaxel
      with adjuvant radiation for stage 3 prostate cancer after prostatectomy (PSA undetectable - &lt;
      2.0 ng/mL). and for patients with persistent or rising PSA post prostatectomy (PSA &gt;0.1 - &lt;
      2.0 ng/mL).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Cabazitaxel With Concurrent Adjuvant Radiation</measure>
    <time_frame>2 mos</time_frame>
    <description>The MTD was not determined secondary to the study closing early. That being said the numbers provided below show that 4 patients were treated on study to aide in the investigation of the MTD. Only 1 dose was fully evaluated which was 5mg/m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Toxicity Associated With Cabazitaxel and Adjuvant Radiation Following Prostatectomy for Patients With Stage 3 Prostate Cancer and for Patients With a PSA Elevation Post-Prostatectomy.</measure>
    <time_frame>During study treatment (approximately 8 weeks) through 30 days post treatment, approximately 12 weeks.</time_frame>
    <description>Assess toxicity using CTCAE version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel and radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2</description>
    <arm_group_label>Cabazitaxel and radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Conditions for Patient Eligibility

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Radical prostatectomy for adenocarcinoma of the prostate with at least one of the
             following:

               -  Extracapsular tumor extension,

               -  Positive surgical margins,

               -  Seminal vesicle invasion

               -  Regional lymph node positive (N1)

               -  Post-prostatectomy PSA of &gt; 0.1 - &lt; 2.0 ng/mL at least 6 weeks after
                  prostatectomy and within 30 days of registration in a patient with T2 or T3
                  disease at prostatectomy.

          -  No distant metastases.

          -  No prior pelvic or prostate radiation or chemotherapy for prostate cancer.

          -  ECOG performance status 0-1.

          -  Age&gt;18.

          -  Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥
             1500 cells/mm3; platelet count ≥100,000 cells/mm3, Creatinine ≤ 1.5X upper limit of
             normal (if creatinine clearance 1.0-1.5x ULN, creatinine clearance will be calculated
             according to Chronic Kidney Disease Epidemiology Group formula and patients with
             creatinine clearance &lt; 60 ml/min should be excluded),19 .Hgb &gt; 9.0 g/dl, total
             bilirubin ≤ 1x ULN, and AST or ALT ≤ 2.5 x ULN.

          -  Life expectancy of at least 1 year.

          -  Must not have uncontrolled severe, intercurrent illness.

          -  No concurrent anticancer therapy.

          -  Men of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

          -  Signed study-specific consent form prior to study entry.

          -  Conditions for Patient Ineligibility

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Evidence of distant metastases (M1). Equivocal bone scans are allowed if plain films
             are negative for metastasis.

          -  Major medical or psychiatric illness which, in the investigator's opinion, would
             prevent completion of treatment and would interfere with follow-up.

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 2 years (For example, carcinoma in situ of the oral cavity or bladder
             are permissible).

          -  History of severe hypersensitivity (&gt; grade 3) reaction to Cabazitaxel or other drugs
             formulated with polysorbate 80.

          -  History of severe hypersensitivity (&gt; grade 3) to docetaxel.

          -  Any uncontrolled severe, intercurrent illness (including uncontrolled diabetes)

          -  At least 4 weeks since any major surgery.

          -  Patients on concurrent anticancer therapy.

          -  PSA &gt; 2ng/ml

          -  Concurrent or planned treatment with strong inhibitors or inducers of cytochrome p450
             3A4/5 (a one-week wash out period is necessary for patients who are already on these
             treatments (see appendix H and I)

          -  Androgen deprivation therapy started prior to prostatectomy for &gt; 6 months duration;

          -  Neoadjuvant chemotherapy prior to prostatectomy;

          -  Prior cryosurgery or brachytherapy of the prostate; prostatectomy should be the
             primary treatment and not a salvage procedure;

          -  Prior pelvic radiotherapy;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Safran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brown University Oncology Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>anthony mega, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lifespan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <results_first_submitted>July 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2015</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Dr Anthony Mega</investigator_full_name>
    <investigator_title>Priniciple Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radical prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cabazitaxel and Radiation</title>
          <description>Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
Cabazitaxel: Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cabazitaxel and Radiation</title>
          <description>Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
Cabazitaxel: Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="56" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of Cabazitaxel With Concurrent Adjuvant Radiation</title>
        <description>The MTD was not determined secondary to the study closing early. That being said the numbers provided below show that 4 patients were treated on study to aide in the investigation of the MTD. Only 1 dose was fully evaluated which was 5mg/m2</description>
        <time_frame>2 mos</time_frame>
        <population>while 5 participants were enrolled only 4 completed treatment as patients # 5 only received part of day 1 therapy secondary to an AE and therefore is not included in the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel and Radiation</title>
            <description>Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
Cabazitaxel: Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of Cabazitaxel With Concurrent Adjuvant Radiation</title>
          <description>The MTD was not determined secondary to the study closing early. That being said the numbers provided below show that 4 patients were treated on study to aide in the investigation of the MTD. Only 1 dose was fully evaluated which was 5mg/m2</description>
          <population>while 5 participants were enrolled only 4 completed treatment as patients # 5 only received part of day 1 therapy secondary to an AE and therefore is not included in the assessment.</population>
          <units>mg/m2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">only the 5mg/m2 dose was evaluated due to the study closing early and MTD was not determined)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Toxicity Associated With Cabazitaxel and Adjuvant Radiation Following Prostatectomy for Patients With Stage 3 Prostate Cancer and for Patients With a PSA Elevation Post–Prostatectomy.</title>
        <description>Assess toxicity using CTCAE version 4.0</description>
        <time_frame>During study treatment (approximately 8 weeks) through 30 days post treatment, approximately 12 weeks.</time_frame>
        <population>Number of patients who experienced a toxicity on the study. Of note, there were no serious adverse events on this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Cabazitaxel and Radiation</title>
            <description>Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
Cabazitaxel: Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Toxicity Associated With Cabazitaxel and Adjuvant Radiation Following Prostatectomy for Patients With Stage 3 Prostate Cancer and for Patients With a PSA Elevation Post–Prostatectomy.</title>
          <description>Assess toxicity using CTCAE version 4.0</description>
          <population>Number of patients who experienced a toxicity on the study. Of note, there were no serious adverse events on this trial.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of informed consent to approximately 30 days post last dose of drug- approximately 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cabazitaxel and Radiation</title>
          <description>Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
Cabazitaxel: Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>anorexia/decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>glucose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>hemmorhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypersensitivity rxn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Potassium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>myalgia/ malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain- leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>pain-abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>WBC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anthony Mega</name_or_title>
      <organization>BrUOG</organization>
      <phone>4018633000</phone>
      <email>kayla_rosati@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

